| Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. | |
| | |
MedLine Citation:
|
PMID: 10655439 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. PATIENTS and METHODS: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. RESULTS: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty-nine patients were randomly assigned to FAC and 39 to FAC followed by high-dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P =.35), and 3-year survival rates were 77% and 58%, respectively (P =.23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. CONCLUSIONS: No relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial. |
| | |
Authors:
|
G N Hortobagyi; A U Buzdar; R L Theriault; V Valero; D Frye; D J Booser; F A Holmes; S Giralt; I Khouri; B Andersson; J L Gajewski; G Rondon; T L Smith; S E Singletary; F C Ames; N Sneige; E A Strom; M D McNeese; A B Deisseroth; R E Champlin |
Related Documents
:
|
8083119 - The influence of young age on outcome in early stage breast cancer. 22396039 - Pretargeted radioimmunotherapy (prait) in medullary thyroid cancer (mtc). 22234099 - Immature teratoma of the ovary: a clinicopathological study of 28 cases. 6464959 - Breast cancer concepts. 22793259 - Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. 12449469 - Status of lymph node staging. 11355929 - Treatment of acute promyelocytic leukaemia. 9503489 - Radiotherapeutic management of bulky cervical lymphadenopathy in squamous cell carcinom... 1888359 - Cancer of the breast: a study of 1520 consecutive patients operated on between 1960 and... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of the National Cancer Institute Volume: 92 ISSN: 0027-8874 ISO Abbreviation: J. Natl. Cancer Inst. Publication Date: 2000 Feb |
Date Detail:
|
Created Date: 2000-02-28 Completed Date: 2000-02-28 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7503089 Medline TA: J Natl Cancer Inst Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 225-33 Citation Subset: IM |
Affiliation:
|
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. ghortoba@notes.mdacc.tmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Breast Neoplasms / drug therapy*, pathology, surgery* Chemotherapy, Adjuvant Cyclophosphamide / administration & dosage Disease-Free Survival Doxorubicin / administration & dosage Drug Administration Schedule Female Fluorouracil / administration & dosage Follow-Up Studies Hematopoietic Stem Cell Transplantation* Humans Lymphatic Metastasis Middle Aged Neoadjuvant Therapy Prospective Studies Radiotherapy, Adjuvant Survival Analysis Transplantation, Autologous Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
2P30CA1667223/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/CAF protocol; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil |
| Comments/Corrections | |
Comment In:
|
J Natl Cancer Inst. 2000 Aug 2;92(15):1271-2
[PMID:
10922417
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resista...
Next Document: Testing reminder and motivational telephone calls to increase screening mammography: a randomized st...